 |
Accele Biopharma (“Accele”) and Accele Venture Partners, a related special purpose venture fund, were formed to create a capital-efficient mechanism to identify, finance and manage groundbreaking early stage life science technologies that have the potential to dramatically improve human healthcare, have strong commercial promise and have the potential for generating early proof of concept data. |
 |
Aerie’s mission is to discover and develop novel, first-in-class medications that help patients with glaucoma preserve their sight. Aerie’s products have been developed to be highly effective, safe, and compatible with other glaucoma drugs, while offering the convenience of once-daily dosing. Patients need new and better choices to treat their glaucoma, and Aerie plans on delivering just that. Aerie is a privately held clinical stage pharmaceutical company with three innovative products in late Phase 2 development, the first two of which could reach the market as early as 2016. All of Aerie’s intellectual property is fully owned. Aerie’s offices are located in Bedminster, NJ and Research Triangle Park, NC. |
 |
Alkermes is a leader in innovative medicines that address the unmet needs and challenges of people living with debilitating diseases. As a fully integrated global biopharmaceutical company, Alkermes applies our scientific expertise, proprietary technologies, and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease. |
 |
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. |
 |
The Biotechnology Industry Organization (BIO) is the world’s largest biotechnology trade association. BIO is a 501(c)(6) non-profit organization headquartered in Washington, D.C. We provide advocacy, business development, and communications services for more than 1,100 members worldwide. It is our mission to be the champion of biotechnology and the advocate for our member organizations – both large and small. |
 |
Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease,diabetes, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders. |
 |
CellAegis focuses on Remote Ischemic Conditioning (RIC) which activates innate mechanisms of metabolic protection and has the potential to revolutionize the treatment of ischemic-related reperfusion injury. In cardiovascular care, the potential impact may be similar to that of stents in the cath lab three decades ago. |
 |
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. |
 |
Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS/LODOTRA, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company’s strategy is to develop, acquire, in-license and/or co-promote additional innovative medicines where it can execute a targeted commercial strategy in specific therapeutic areas while taking advantage of its commercial strengths and the infrastructure the Company has put in place. |
 |
Idenix Pharmaceuticals, Inc. is engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Building on its expertise in nucleoside chemistry and other small molecule chemistry and biology, the company is well positioned to become a leader in antiviral pharmaceuticals. Idenix’s current focus is on the treatment of hepatitis C virus (HCV) infections. The company has previously discovered and developed antivirals for the treatment of hepatitis B virus (HBV) and HIV/AIDS. |
 |
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to manage the care of heart transplant patients. |
 |
Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the Central Nervous System (CNS). |
 |
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan’s primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. |
 |
Mesoblast is developing biotherapeutics based on its proprietary cell-based technologies. The Company’s technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat a broad range of conditions with major unmet medical needs. |
 |
Nicox is a new international player in the ophthalmic market building a diversified portfolio of innovative therapies and diagnostic tools addressing the needs of eyecare practitioners and patients around the world. |
 |
Nodality is an innovative biotechnology company advancing discovery, development and use of transformative therapies by revealing functional and systems biology. We focus on unmet medical needs in immunology, inflammation, cancer immunotherapy and oncology. Combining our expertise and proprietary technology, Single Cell Network Profiling, we deliver on the promise of precision medicine by increasing disease understanding, mapping drug activity, and developing tests for patient stratification to improve clinical outcomes for patients. |
 |
Palatin Technologies, Inc. (NYSE Amex: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Our programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. |
 |
Polynoma is a private oncology-focused biotechnology company, currently developing a therapeutic vaccine for the treatment of melanoma. Headquartered in San Diego, California, Polynoma’s technology was founded by and is the life’s work of renowned clinical Professor of Dermatology, the late Jean-Claude Bystryn. |
 |
Savient’s mission is to develop and commercialize pharmaceutical specialty products. On September 14, 2010 the Food and Drug Administration (FDA) approved KRYSTEXXA® (pegloticase). |
 |
Teva’s business is closely aligned with market needs worldwide. A leader with an unparalleled global footprint, we think and act locally while expressing a powerful entrepreneurial spirit. Today, Teva is spearheading the development, production and marketing of a broad range of specialty medicines, generic medicines and active pharmaceutical ingredients (API), OTC products and new therapeutic entities. Our portfolio of pharmaceutical products is comprehensive and strong, and extends to all major therapeutic areas and dosage forms. We produce more than 1,000 molecules and 73 billion tablets and capsules at 75 manufacturing plants every year. Building on a profound foundation of success, we are transforming the way we work while focusing on evolving medical, societal and consumer needs. |
 |
Veracyte is pioneering the emerging field of molecular cytology. We are developing molecular tests designed to improve the diagnostic accuracy of cytology samples, thereby helping to increase the utility of these minimally invasive procedures as an alternative to surgical biopsy. |
